The European Medicines Agency has suspended the use of Picato, an ingenol mebutate-containing product for actinic keratosis, because of concern over its propensity to cause skin cancer.
The EMA’s pharmacovigilance committee, the PRAC, has also confirmed its recommendation that high-strength estradiol-containing creams should be used for a maximum of four weeks to avoid the possibility of